Munich, Germany

Ralf Leibinger

This inventor holds 1 USPTO granted patent and 6 published patent applications and 2 EPO patents. Top assignee: Karl Leibinger Asset Management Gmbh & Co. Kg.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ralf Leibinger - Innovator in Mandibular Joint Prosthesis Design

Introduction

Ralf Leibinger is an inventor based in Munich, Germany. He is associated with Karl Leibinger Asset Management GmbH & Co. KG. Although he currently holds no granted patents, his work focuses on innovative solutions in the field of mandibular joint prosthesis design.

Latest Patent Applications

Ralf Leibinger has submitted several notable patent applications. One of his latest applications is titled "Method for Designing a Mandibular Joint Prosthesis and Corresponding Production Method." This method provides a systematic approach for designing a mandibular joint prosthesis tailored to a patient's specific skull side. It involves matching a standardized model of the mandibular joint to a graphic representation of the patient's healthy skull side, allowing for detailed adaptations. Another significant application is for an "Implantable Mandibular Joint Prosthesis and Corresponding Production Method." This prosthesis includes a first implant part with an artificial condyle that attaches to the lower jawbone and a second implant part with a joint surface that connects to the cranium. The design incorporates both metal and plastics materials to ensure functionality and compatibility.

Conclusion

Ralf Leibinger's contributions to the field of mandibular joint prosthesis design reflect his commitment to innovation and patient-specific solutions. His latest patent applications demonstrate his expertise and potential impact in the medical device industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…